Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Curcugen is a branded **bioavailability-enhanced curcumin nutraceutical ingredient** derived from *Curcuma longa* and developed by DolCas Biotech, then commercialized with IFF Health Sciences. It is a water-dispersible whole turmeric extract standardized to approximately 50% curcuminoids and includes native turmeric essential oils and resins, produced using the SELF-D technology platform to optimize turmeric oleoresin delivery. Rather than acting as a single highly selective pharmaceutical ligand, Curcugen delivers curcuminoids with broad **anti-inflammatory and antioxidant** activity that have been studied in dietary supplement settings for joint health, osteoarthritis-related pain, digestive health, mood support, and general inflammatory balance, typically as an **oral** supplement at daily doses around 500 to 1000 mg.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Curcugen.